Efavirenz/lamivudine/tenofovir disoproxil fumarate

Drug Profile

Efavirenz/lamivudine/tenofovir disoproxil fumarate

Alternative Names: 3TC/EFV/TDF; Efavirenz 400mg/lamivudine 300mg/tenofovir disoproxil fumarate 300mg; Efavirenz 600mg/lamivudine 300mg/tenofovir disoproxil fumarate 300mg; Efavirenz/tenofovir disoproxil fumarate/lamivudine; EFV/3TC/TDF; EFV/TDF/3TC; Lamivudine/efavirenz/tenofovir disoproxil fumarate; Lamivudine/tenofovir disoproxil fumarate/efavirenz; TDF/3TC/EFV; Telura; Tenofovir disoproxil fumarate/efavirenz/lamivudine; TLE400

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator Matrix Laboratories
  • Developer Mylan; Mylan Laboratories Limited; The HIV Netherlands Australia Thailand Research Collaboration
  • Class Antiretrovirals; Benzoxazines; Deoxyribonucleosides; Dideoxynucleosides; Phosphonic acids; Purines; Pyrimidine nucleosides
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 20 Mar 2017 Preregistration for HIV-1 infections (In adolescents, In adults, Treatment-naive) in USA (PO)
  • 20 Mar 2017 The 2016 WHO Consolidated Guidelines recommend efavirenz/lamivudine/tenofovir disoproxil fumarate (400/300/300) as an alternative first-line treatment for HIV infections in adults and adolescents
  • 20 Mar 2017 The US FDA issues tentative approval to efavirenz/lamivudine/tenofovir disoproxil fumarate (400/300/300) for HIV infections (Treatment-naive, In adults, In adolescents) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top